BACKGROUND: @entity1 presenting with peritoneal metastases (PM) of @entity14 ( @entity14 ) can be curatively treated with @entity1104 ( @entity1104 ) and hyperthermic intraperitoneal chemotherapy (HIPEC). Angiogenesis is under control of multiple molecules of which @entity7738 , @entity1570 , @entity436 , and @entity7 are key players. We investigated these angiogenesis-related markers and their prognostic value in @entity1 with PM arising from @entity14 treated with @entity1104 and HIPEC. @entity1 AND METHODS: Clinicopathological data and tissue specimens were collected in 2 tertiary referral centers from 52 @entity1 who underwent treatment for isolated PM of @entity14 . Whole tissue specimens were subsequently analyzed for protein expression of @entity7738 , @entity1570 , @entity436 , and @entity7 by immunohistochemistry. Microvessel density (MVD) was analyzed by @entity2279 immunohistochemistry. The relationship between @entity1349 ( @entity1349 ) and protein expression as well as other clinicopathological characteristics was analyzed. RESULTS: Univariate analysis showed that high peritoneal @entity5 index (PCI), resection with @entity66 and high expression of @entity7 were negatively correlated with @entity1349 after treatment with @entity1104 and HIPEC (P  <  0.01, P  <  0.01, and P  =  0.02, respectively). However, no association was found between the other markers and @entity1349 (P  >  0.05). Multivariate analysis showed an independent association between @entity1349 and PCI, resection outcome and @entity7 expression (multivariate HR: 6.1, 7.8 and 3.8, respectively, P   <=  0.05). CONCLUSIONS: An independent association was found between high @entity7 expression levels and worse @entity1349 after @entity1104 and HIPEC. The addition of @entity7 expression to the routine clinicopathological workup could help to identify @entity1 at risk for early treatment failure. Furthermore, @entity7 may be a potential target for adjuvant treatment in these @entity1 .

Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity7738 :: ('3091', 'Gene') :: ['HIF1a'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity7 :: ('7422', 'Gene') :: ['VEGF'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1570 :: ('6387', 'Gene') :: ['SDF1'] @entity2279 :: ('5175', 'Gene') :: ['CD31'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer', 'CRC'] @entity1104 :: ('MESH:D000267', 'Disease') :: ['CRS', 'cytoreductive surgery'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity436 :: ('7852', 'Gene') :: ['CXCR4']
@entity14 :: (MESH:D015179,Disease) :: ['Colorectal Cancer']
